CeriBell Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. My name is Bill Plovanic. I am a Senior Medical Device Analyst here with Canaccord, and welcome to our MedTech, Diagnostics and Digital Health & Services Forum. I always have to read that because it is a mouthful. With us next, we have CeriBell. It is going to be a fireside chat with Scott Blumberg, CFO. First of all, Scott, thanks for joining today.
Yeah, thanks for having us.
I will kick this off. You just delivered another 30% growth quarter, and if it got hot mic and picked up, it has been crazy. This company has done nothing but beat and raise since the IPO, and I think you have been punished at some times, and finally, you are not being punished, which it is just been an amazing ride so far. But you posted 35 net new accounts, record same-store utilization, heading into what may be the most product-rich stretch since the IPO with the delirium launch, the Omni coming, limited release now, and a couple of software clearances. Before we really dive in here, help us understand how the vision of the company has evolved since the IPO. I mean, when it was IPO, it was seizure detection tool, and now you are becoming a broader brain monitoring platform.
Not just that evolution, but as you think of the competitive landscape, who do you view as your competitors?
Yeah, the basic story has not changed, but our trajectory along that journey has. For years, even before the IPO, we've laid out a multi-phase vision. The first step was becoming the standard of care for seizure detection, and then the second phase is to become a comprehensive critical care brain monitor. With the introduction of delirium, which is our second major new patient population indication, and the Omni, which was designed for multimodal brain monitoring, we're bringing that vision to life. As far as competition goes, the reality is we're bringing out a tool that replaces longstanding traditions and not directly competitive with any other type of novel tool. So in seizure, the standard of care is conventional EEG, which was designed quite literally a century ago for detection of epilepsy in outpatient clinics.
For delirium, the competition is a literal survey called the CAM-ICU that nurses fill out and ask the patient to engage. What we're doing is bringing diagnostics, bringing rapid diagnostics using a device, overlaying AI, bringing continuous monitoring to a group of patients who've never really had that in any way, shape, or form.
All right. We're going to start off with the core business utilization here. So, you cited record double-digit year-over-year same-store utilization growth, and you said that you've expanded into more departments year to date than all of 2025. Which parts of the playbook, department expansion, physician engagement, protocolization, are doing the most work, and how much runway is left given your top accounts monitor roughly three times the number of patients in the average account?
Those are the three core strategies, absent things like delirium, where we're overlaying new technologies into the install base, and they all are contributors. I think we called out specifically department expansion this year because it was a bit more of a contributor relative to the other two than it was last year. What we said is in 2026, we've expanded to more departments in the first three quarters than we did in all of 2025. So you can see the acceleration there. We've also really kind of gone back to basics as we've expanded the CAM team and they've become more mature. We've really doubled down on the core provider engagement, making sure all doctors are trained, making sure that workflows are identified, new patient populations are brought into the fold, and they've all been meaningful.
This has been, over the last two quarters, probably the biggest step forward we've seen in same-store growth since our IPO. We saw positive momentum in Q2, and then the first quarter of double-digit percent utilization growth in Q3.
It's all working. On that topic, I mean, I've been doing this longer than I care to admit, but I don't think I've ever seen a company post-IPO add accounts, and the bigger the account base gets, see utilization per account go up.
It's just large numbers. Typically, each incremental account is lower utilization. But this quarter, we had the headband sold per active account was 50.4. That's our math. That was only up 7% year over year. You said it was double digit. How much the purchases ran ahead. I mean, how much of a shift did that in kind of what would that have been normalized? If it was 10, a double-digit number, it's more like 51, 52?
Yeah. I think that's the way to think about it. We run the entire business on literal usage. Because our device is cloud-enabled, unlike a lot of medical devices, we know actually when it's being used with precision. So we use that for our internal analytics. We use that for our compensation of our team. When we said double digit, we're talking about actual usage. Customers buy and use at different rates. They tend to buy more than they use because they need to stock inventory. It was a little bit relative to the usage lower in Q3. We didn't think the magnitude. To give you a kind of an idea on the magnitude, we didn't think the magnitude was sufficient to make a proactive comment. But you're smart, you did the math, and you saw 7% isn't double digit.
That is the difference between seven and low double digit is the purchasing patterns. As far as our guide for Q4, we assume that that normalizes to the level we've seen historically, but does not recorrect to account for the difference we saw in Q3.
Got you. One of the big thesis going into the year was just all the reps that were added, and they're going to start gaining traction and contributing. On that topic, you had a record number of new accounts. How do we think about the cadence of account adds going forward? Is it maintain this record number? Does it accelerate beyond that record number? Is the rest of this rep become more efficient?
Yeah. How do we think about it?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
